【why are there no boats on klamath lake】Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020
STAMFORD,why are there no boats on klamath lake Conn., May 04, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (
CARA
), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020, at 4:30 p.m. ET to report first quarter 2020 financial results and provide a corporate update.
To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 3875739. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at
www.CaraTherapeutics.com
.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis (PBC).
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
View comments
相关文章
- Dublin, May 05, 2020 (GLOBE NEWSWIRE) -- The"Plasma Protein Therapeutics Market - Growth, Trends, an2024-09-29
Drayage update: The Future Of EDI (With Video)
Social, political and economic conditions at the national and global levels are changing at breaknec2024-09-29Were Hedge Funds Wrong About Crowding Into RealPage, Inc. (RP)?
In this article we are going to use hedge fund sentiment as a tool and determine whether RealPage, I2024-09-29Billionaire Warren Buffett Divests Airline Stakes, Sees No ‘Attractive’ Investments
Billionaire Warren Buffett said Saturday that its investment conglomerate Berkshire Hathaway (BRK.A)2024-09-29Apollo Endosurgery, Inc. Reports First Quarter 2020 Results
Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ETAUSTIN, TX / ACCESSWIRE / May2024-09-29Evotec to Attend Upcoming Investor Conferences
HAMBURG, GERMANY / ACCESSWIRE / November 4, 2020 /Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/Tec2024-09-29
最新评论